The global animal biotechnology market size was valued at USD 27.18 billion in 2023 and is anticipated to reach around USD 65.72 billion by 2033, growing at a CAGR of 9.23% from 2024 to 2033.
Molecular biology methods are applied in animal biotechnology to genetically alter animals or change their genomes to make them more suitable for industrial, medicinal, or agricultural use. Recent developments in gene expression, metabolic cell profiling, and animal genome sequencing have made animal biotechnology advances more uncomplicated. Recent advancements in genome editing technologies, such as Zinc Finger Nucleases, TALENS, and CRISPR-Cas systems, have made generating animal genetic changes that enhance agricultural productivity, health and well-being, and disease resistance easier.
The U.S. animal biotechnology market size was exhibited at USD 7.11 billion in 2023 and is projected to be worth around USD 17.52 billion by 2033, poised to grow at a CAGR of 9.44% from 2024 to 2033.
North America dominated in the animal biotechnology market in 2023. The United States Food and Drug Administration (FDA) and the Canadian Food Inspection Agency (CFIA) are two examples of established regulatory bodies in North America that offer precise standards and frameworks for developing and approving biotechnological goods. These organizations guarantee goods' efficacy and safety, promoting customer confidence and market access. Rigorous intellectual property regulations well protect biotechnological innovations in the United States and Canada. This instills confidence in businesses to engage in R&D since they know their innovations will be protected from unlawful usage.
Asia-Pacific is observed to be the fastest-growing in the animal biotechnology market during the forecast period. Increasing disposable incomes result from the rapid economic expansion of Southeast Asian, Indian, and Chinese nations. This, in turn, fuels the demand for premium animal products and cutting-edge veterinary care. Biotechnological advancements find fertile ground as farming and animal husbandry operations become more advanced and efficient due to the growing urban population.
Anand Srivastava of the National Institute of Animal Biotechnology (NIAB) and his colleagues used a computational biology method to build a multi-epitope protein, a collection of numerous tiny peptides combined into a single continuous protein fragment, as a potential LSD virus vaccine.
| Report Attribute | Details |
| Market Size in 2024 | USD 29.69 Billion |
| Market Size by 2033 | USD 65.72 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 9.23% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, Animal Type, Application, End-use, and Regions |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Merck & Co., Inc., Virbac, Elanco, Idexx Laboratories, NXGN Management, LLC, Heska Corporation, Zoetis, Boehringer Ingelheim International GmbH, Biogénesis Bagó, Indian Immunologicals Ltd., HESTER BIOSCIENCES LIMITED, Kareo, Inc., and Others. |
Drivers
Rising need to develop genetically modified therapeutic proteins
Therapeutic proteins can replace an aberrant or insufficient protein in each condition. Moreover, they can increase the body's supply of healthy protein to lessen the effects of chemotherapy and illness. Proteins that have been genetically modified can be made to resemble better the natural proteins they are meant to replace, or they can be made to function longer by including sugars or other compounds.
Among the macromolecular therapeutic proteins are cytokines, IFNs, and monoclonal antibodies. CYP enzymes are not suitable substrates for proteins. Generally, they are eliminated through renal filtration or broken down into smaller peptides or amino acids in various tissues by phagocytic cells that circulate or target antigen-containing cells. This is what fuels the expansion. This drives the growth of the animal biotechnology market.
Application in cancer treatment
Cancer is a hotspot for medical research because it has historically been the subject of global human interest. Researchers utilize animals in their studies to learn more about the mechanisms underlying cancer, including tumor growth and dissemination, and to create novel approaches to diagnosing, treating, and preventing the illness. Mice whose tumors can resemble those of human cancer patients are the primary tool used in research at the ICR. Research on cancer in mice replicates the intricate processes involved in tumor growth and metastasis in humans.
Animal models can be used for gene therapy research, cancer treatment screening, and the biochemical and physiological mechanisms of cancer incidence and progression in objects.
Restraint
High development costs pose challenge for small players
The development of biotechnology solutions necessitates pricey cutting-edge equipment and knowledge. Small businesses frequently lack the funding essential to invest in the cutting-edge labs, and knowledgeable staff required for creative R&D. Small players must negotiate a complicated web of national, international, and local laws, each with specific criteria for compliance. Because businesses frequently need to pay regulatory specialists or consultants to manage this process, this increases the financial burden. This limits the growth of the animal biotechnology market.
Opportunity
Growing awareness regarding animal health and welfare
Animal welfare, as defined by the Farm Animal Welfare Council (FAWC), concerns the physical and emotional health of animals. Another name for it is the "quality of life" of an animal. Legally speaking, a person's need to assume responsibility for and care for animals protects animal welfare.
Even in the most developed nations today, there is still a noticeable lack of dedication to animal care, primarily due to a lack of public knowledge and responsibility for pet ownership. Since the Internet and the media are so widely accessible, information regarding unresolved pet-related queries is easily obtainable. As a result, a veterinarian's job is more comprehensive, mainly when he provides his patients with information that helps them understand their condition and prevents misunderstandings.
The vaccines segment held the largest revenue share of over 28.68% in 2023. The growth of the vaccine segment is primarily attributed to the increasing burden of animal infections. These infections are naturally transmitted from animals to humans owing to contaminated food and water consumption or direct communication with infected humans or animals. Vaccination is an effective way to lower the disease burden in animals, and it plays an important role in preventive healthcare and disease control. Additionally, the increase in vaccine introductions for animals by the key market players is projected to drive the segment. In December 2023, Indian Immunologicals Ltd. introduced Goat Pox Vaccine (Raksha Goat Pox). Likewise, in May 2023, Boehringer Ingelheim India released its poultry vaccine VAXXITEK HVT+IBD. Such launches will lead to the increased adoption of vaccines, fueling segment growth.
The diagnostics tests segment is anticipated to witness exponential growth throughout the forecast period. The growth in this segment is attributed to factors, such as growing animal health expenditure, rising incidence of zoonotic diseases, increase in the number of veterinary practitioners, and increasing disposable income levels in developing territories. Besides, the overall market is determined by deeply understanding the demand for these products from veterinary hospitals, clinics, labs, etc., and increasing R&D investments from industry players. In August 2021, INDICAL BIOSCIENCE GmbH acquired the Check-Points, Dutch R&D-focused corporation. INDICAL is a global leader in the advancement of complete solutions for molecular and immunological veterinary testing.
The preventive care of animals segment held the largest revenue share of over 28.45% in 2023 due to the growing adoption of companion animals. The advent of pet parents as part of the pet humanization trend is a key revenue-generating trend in the market. Besides, an international survey by HABRI and Zoetis indicates a direct relationship between the human-animal bond and consistent veterinary care. The study including participants from the U.S., France, the U.K., Spain, Germany, Japan, Brazil, and China showed a clear global phenomenon of the improved bond between humans and pets, with 95% of respondents stating that they consider their pets to be a part of the family. Thus, such a human-animal bond advances better preventive care.
The drug development application is anticipated to witness exponential growth throughout the forecast period. Leveraging the monoclonal antibodies in animal health generated great potential to address unmet needs. For instance, in September 2023, Boehringer Ingelheim and Invetx announced that they have entered a collaboration agreement to develop innovative, species-specific monoclonal antibody biotherapeutics targeting a broad range of infections in the veterinary species, primarily focused on dogs and cats. This partnership will address Boehringer Ingelheim’s commitment to delivering unmet needs in the rapidly growing animal health biotechnology market.
The livestock segment held the largest share of over 64.86% in 2023. Livestock is becoming increasingly vital in the growth of agriculture in developing nations. The contributions made by livestock to both agriculture and gross domestic product have risen in various nations. The demand for livestock products is a function of income in different parts of the world. The growing urban population and changes in diet and lifestyle are promoting growth in livestock production, thus contributing to the segment growth. Furthermore, government initiatives undertaken for livestock vaccinations promote market growth.
For instance, in June 2023, Indonesia launched a countrywide livestock vaccination program as the number of cattle affected with foot and mouth disease surged to more than 151,000. In the livestock segment, cattle held the largest revenue share in 2023. The U.S. is home to about 100.8 million cattle and calves as of 2022. The companion animal type segment is likely to grow lucratively during the forecast period owing to an increase in the demand for efficient animal care and the pet-human bond owing to the associated health benefits. Banfield Pet Hospital, in January 2023, confirmed a huge boom in U.S. pet ownership, thus supporting the segment growth.
The veterinary hospitals and clinics segment held the largest revenue share of over 72.85% in 2023 and is anticipated to continue leading the market over the forecast period. The availability of a wide range of treatment and diagnostic options in veterinary hospitals and clinics is a high-impact rendering growth driver for this segment. An increase in the incidence of zoonotic diseases caused by globalization and climate change is expected to drive the demand for diagnostic procedures, which is expected to drive the point-of-care testing/in-house testing segment in the coming years.
The others segment is expected to witness the fastest growth over the forecast period. Veterinary research institutes and universities are expected to grow at a lucrative rate over the forecast period. This can be attributed to the growing R&D funding to develop advanced diagnostic tools and therapeutically advanced vaccines and medicines. Research institutes are primarily responsible for the development of these diagnostics.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Animal Biotechnology market.
By Product
By Animal Type
By Application
By End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers